The divergent management of melasma: a 2026 clinical review comparing traditional standards in lighter photo types to novel athermal and biological modalities in Fitzpatrick IV–VI

Vollständiger Abstract

Worum geht es in dieser Arbeit?

Melasma (historically chloasma) remains a complex, recalcitrant pigmentary disorder affecting millions worldwide. This article elucidates the paradigm shift in management strategies observed in early 2026 for Fitzpatrick III-VI, its comparison with Fitzpatrick I–III, and the transition from aggressive mono-therapies to a multi-layered, synergistic approach. To locate, select, and extract relevant data, a comprehensive search of recent clinical protocols and emerging technological studies was conducted. This literature was systematically synthesized to evaluate novel therapeutic targets, specifically vascular modulation, basement membrane repair, and epigenetic modification in Fitzpatrick IV–VI. Key focus areas included the safety of "hydroquinone (HQ)-free" maintenance agents, systemic use of low-dose tranexamic acid (TXA), and athermal technologies. Findings revealed a definitive phototype-dependent divergence in clinical outcomes. In Fitzpatrick I–III, traditional cytotoxic agents (HQ) and photothermal devices yielded high clearance with minimal sequelae. Conversely, in Fitzpatrick IV–VI, these same aggressive modalities statistically correlated with severe adverse events, including exogenous ochronosis and post-inflammatory hyperpigmentation. For melanin-rich skin, synthesized data established biological modulators (5% stabilized cysteamine, Thiamidol) and systemic stabilizers (low-dose oral TXA) as superior alternatives, effectively suppressing vascular endothelial growth factor without melanocyte cytotoxicity. Furthermore, athermal devices (picosecond 1064 nm) and insulated radiofrequency (RF) micro-needling demonstrated significant efficacy in clearing dermal pigment and repairing basement membrane degradation without triggering thermal spread. These findings confirm that successful management of Fitzpatrick IV–VI requires a multi-layered strategy of cellular modulation, vascular suppression, and dermal-epidermal junction repair. Methods: To arrive at the synthesized data, a comprehensive search was conducted to locate, select, and extract relevant findings from recent clinical protocols and emerging technological studies. This literature was systematically reviewed to evaluate novel therapeutic targets, specifically tailored for Fitzpatrick IV–VI skin. The extraction process prioritized studies addressing epigenetic modification, basement membrane repair, and vascular modulation to ensure a robust comparison against traditional therapies.